SCHEMBL2483459

SCHEMBL2483459

CC(C)S(=O)(=O)N1CCN(c2ccc(Nc3cc(NCc4cc(F)cc(C(F)(F)F)c4)c(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 7/20 0.47
SYK P43405 4/20 0.45
JAK3 P52333 7/20 0.44
JAK2 O60674 3/20 0.44
IRAK4 Q9NWZ3 2/20 0.44
JAK1 P23458 2/20 0.44
TYK2 P29597 2/20 0.44
CYP17A1 P05093 2/20 0.41
CYP21A2 P08686 2/20 0.41
CYP11B1 P15538 1/20 0.39
CHEK1 O14757 1/20 0.39
NUAK1 O60285 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
FLT4 P35916 1/20 0.39
FLT3 P36888 1/20 0.39
RPS6KA3 P51812 1/20 0.39
MAPK10 P53779 1/20 0.39
MAP3K9 P80192 1/20 0.39
ITK Q08881 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2508033 0.93 STAT6 (0.53) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2502240 0.90 STAT6 (0.51) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2478541 0.86 STAT6 (0.62) STAT6JAK3JAK2IRAK4JAK1
SCHEMBL2485587 0.85 JAK3 (0.49) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2485542 0.85 STAT6 (0.55) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2504310 0.84 JAK3 (0.55) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2507016 0.83 STAT6 (0.53) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2510247 0.83 JAK3 (0.54) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2476949 0.82 STAT6 (0.56) STAT6SYKJAK3JAK2IRAK4
SCHEMBL2506881 0.81 STAT6 (0.54) STAT6SYKJAK3JAK2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA STAT6 8/4885SYK 137/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.